OxTalks will soon be transitioning to Oxford Events (full details are available on the Staff Gateway). A two-week publishing freeze is expected in early Hilary to allow all events to be migrated to the new platform. During this period, you will not be able to submit or edit events on OxTalks. The exact freeze dates will be confirmed as soon as possible.
If you have any questions, please contact halo@digital.ox.ac.uk
Highlights from the presentation: ‘What happens when you blend the medicinal chemistry with the complexity of biology? You get a journey that starts with small molecules and ends with big breakthroughs… (and sometimes, with llamas). In this talk, I’ll share how a foundation in chemistry shaped my approach to biotherapeutics, leading to novel insights in GPCR antibody discovery. Expect science, some surprises, and yes — a few camelid cameos’
Christel Menet, PhD is currently Chief Scientific Officer at Confo Therapeutics.
Christel joined Confo as CSO in 2016 from Galapagos NV, where she was one of the first chemists and later advanced to Director of Medicinal Chemistry. She is the inventor of filgotinib (Jyseleca), commercialized for treatment of moderate to severe active rheumatoid arthritis. Prior to Galapagos, Christel worked at Faust Pharmaceuticals (now Domain Therapeutics), a biotech specializing in GPCR drug discovery. She is an inventor on over 25 patent applications and co-authored numerous publications.
Christel completed her PhD in Organic Chemistry at the University of Manchester in the lab of Prof Jonathan Clayden.
